Drugs / Itolizumab
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05978544 | Dec 2023 → Nov 2025 | acute respiratory distress syndrome | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05986162 | Dec 2023 → May 2025 | adult dermatomyositis | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05823675 | May 2023 → Oct 2024 | acute graft versus host disease | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04128579 | Oct 2019 → Nov 2023 | lupus erythematosus, lupus nephritis | Biocon Limited | Completed | No outcome recorded |
| Phase 1 | NCT04007198 | Jun 2019 → Oct 2021 | asthma | Biocon Limited | Completed | No outcome recorded |
| Phase 1 | NCT02649270 | Oct 2014 → Jun 2015 | psoriasis | Biotech Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03763318 | Jul 2019 → Nov 2022 | acute graft versus host disease | Biocon Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04475588 | May → Jul 2020 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome | Biocon Limited | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05263999 | Apr 2022 → Apr 2025 | acute graft versus host disease | Equillium | Terminated | No outcome recorded |
| Phase 3 | NCT04605926 | Nov 2020 → Apr 2021 | COVID-19 | Biocon Limited | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Itolizumab | “This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.” NCT04605926 ↗ |
| Known as | Bmab 600 | “Itolizumab \[Bmab 600\]” NCT04007198 ↗1“Itolizumab [Bmab600]” NCT05263999 ↗ |
| Known as | EQ001 | “Itolizumab (EQ001) administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses.” NCT05263999 ↗ |
| Known as | T1h | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02649270 ↗ |
| Action | Inhibit | “Itolizumab inhibited CD4 and CD8 T-cell activation and proliferation” PMID 35484649 ↗ Nov 2022 |
| Modality | Monoclonal antibody | “humanized recombinant anti-CD6 monoclonal antibody” NCT02649270 ↗ |
| Route | Intravenous | “by vein” NCT02649270 ↗ |
| Target | CD6 | “anti- CD6 monoclonal antibody” PMID 35484649 ↗ Nov 2022 |